-
-
-
-
-
-
-
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
-
-
-
-
-
-
-
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Can
-
-
-
-
-
-
-
ImmunityBio to Present at the Jefferies London Healthcare Conference
-
-
-
-
-
-
-
ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives
-
-
-
-
-
-
-
ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients
-
-
-
-
-
-
-
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
-
-
-
-
-
-
-
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients
-
1,160,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

